Navigation Links
China-Biotics Files New Patent Applications
Date:9/16/2010

China-Biotics Files New Patent Applications -- SHANGHAI, Sept. 16 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Chemical Click to view news release full screen  

China-Biotics Files New Patent Applications

 

SHANGHAI, Sept. 16 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics" or "the Company"), the leading developer, manufacturer and distributor of probiotics products in China, today announced that it has submitted two new patent applications to the State Bureau of Intellect Property.

The Company's wholly owned subsidiary, Growing Bioengineering (Shanghai) Co. Ltd., located in the Qingpu Industrial Zone, has filed two applications in the areas of heat resistant fermentation technology and probiotics protein beverage.

Mr. Jinan Song, Chairman and CEO of China-Biotics, concluded, "We continue to focus on the development of our proprietary technologies and products to heighten entry barriers for our competitors. After we successfully implemented our incentive plan for product development and production innovations, our sales team and R&D team are now working more closely with each other to develop new products, cut costs and increase productivities. Also, we will be launching more joint R&D programs with leading research institutions in China. Our goal remain intact, to provide the best comprehensive probiotics solutions to our end customers. As the Chinese government continues to address food safety measures and Chinese consumers are increasing their healthcare expenditures, we expect that more and more dairy and animal feed companies will embrace and increase the use of our probiotics products."

About China-Biotics

China-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," "continue," or the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

For more information, please contact: China-Biotics, Inc. Travis Cai Chief Financial Officer Email: traviscai@chn-biotics.com Grayling Kevin Theiss / Shiwei Yin Tel: +1-646-284-9409 Email: kevin.theiss@grayling. com shiwei.yin@grayling.com
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China-Biotics, Inc. Comments on Market Rumors
2. China-Biotics Announces September 20 Investor Day Schedule
3. China-Biotics to Host Investor Day in Shanghai to Discuss Corporate Development Strategy
4. China-Biotics, Inc. Announces US$20 million Share Buyback Program
5. China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
6. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
7. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
8. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
9. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Concord Medical Files 2009 Annual Report on Form 20-F
11. Tongjitang Files 2009 Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis ... the global Fibromyalgia market. The research answers the following ... for Fibromyalgia and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... LA JOLLA, Calif. , Feb. 23, 2017 /PRNewswire/ ... biopharmaceutical company leading the discovery and development of innovative ... quarter and full year 2016 financial results on Thursday, ... Regulus will host a conference call and webcast on ... discuss fourth quarter and full year 2016 financial results ...
Breaking Medicine Technology:
(Date:2/24/2017)... Abilene, Texas (PRWEB) , ... February 24, 2017 , ... ... article that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an ... of this current generation. He explains that the Bible details the current times ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Country Club in Miami Beach to host its Swirl: Miami Wine Tasting Event ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):